Compass Therapeutics, Inc.

As of June 18, 2025, the trend is mildly bullish, supported by bullish MACD and Bollinger Bands on weekly and monthly charts, despite some mixed signals from daily moving averages and the KST.

Compass Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $17 million and a market cap of $302.84 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -50.07%.

As of Jun 18, Compass Therapeutics, Inc. has a market capitalization of 302.84 million and reported net sales of 0.85 million with a net loss of 55.22 million over the last four quarters.